Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Antiviral Drugs

Recommendations of the Advisory Committee on Immunization Practices (ACIP): Information for Health Care Professionals

The information on this page should be considered current for the 2014-2015 influenza season for clinical practice regarding the use of influenza antiviral medications. Also see the current summary of recommendations available at Influenza Antiviral Medications: Summary for Clinicians and a list of related references at Antiviral Guide References.

This page contains excerpts from Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza - Recommendations of the Advisory Committee on Immunization Practices (ACIP). PDF Version [1 MB, 28 pages]

Previously, the neuraminidase inhibitors oseltamivir and zanamivir were the only recommended influenza antiviral drugs. On December 19, 2014 the U.S. Food and Drug Administration approved Rapivab® (peramivir) to treat influenza infection in adults. The antiviral content on the CDC website is in the process of being updated to reflect that change.

Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza - Recommendations of the Advisory Committee on Immunization Practices (ACIP)
available as PDF [1 MB, 28 pages]

Additional Information for Health Care Professionals

Information for the Public

Top